Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development...
NEWARK Calif. May 24 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced the receipt of a Phase 2 Small Business Innovation Research SBIR Grant from the National Institute of...
View ArticleTiGenix NV TIG Pharmaceuticals Healthcare Deals and Alliances Profile Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleSigmoid Pharma Ltd Pharmaceuticals Healthcare Deals and Alliances Profile...
SummarySigmoid Pharma Ltd Sigmoid formerly Sigmoid Biotechnologies Ltd is a developer of therapies for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The company's...
View ArticleProtagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic...
NEWARK Calif. May 25 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced that the company has initiated a Phase 1 clinical study of PTG300 in normal healthy volunteers. PTG300 is...
View ArticleBiosimilars in the treatment of inflammatory bowel disease
Inflammatory bowel disease IBD is mainly characterized by two chronic relapsing immunemediated inflammatory diseases of the gastrointestinal tract Crohns disease and ulcerative colitis. Approximately...
View ArticleImmune Receives Nasdaq Letters
NEW YORK May 26 2017 PRNewswire Immune Pharmaceuticals Inc. NASDAQ IMNP the "Company" announced today that on May 24 2017 the Company received written notice from Nasdaq that the Company has regained...
View ArticleOncobiologics Inc ONSIU Pharmaceuticals Healthcare Deals and Alliances...
SummaryOncobiologics Inc Oncobiologics is a biopharmaceutical company that develops manufactures and commercializes monoclonal antibodies biosimilars in the therapeutic areas of oncology and...
View ArticleNatco Pharma Ltd NATCOPHARM Pharmaceuticals Healthcare Deals and Alliances...
SummaryNatco Pharma Ltd Natco Pharma focuses on the research development manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage...
View ArticleAtlantic Healthcare develops tablet formulations of alicaforsen to treat...
CAMBRIDGE U.K. May 30 2017 GLOBE NEWSWIRE Atlantic Healthcare plc Atlantic Healthcare an emerging transAtlantic pharmaceutical company with a core focus on gastrointestinal GI disorders announces the...
View ArticleProtagonist Therapeutics Enters into Worldwide Agreement with Janssen to...
NEWARK Calif. May 30 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced that the company has entered into a worldwide license and collaboration agreement with Janssen Biotech...
View ArticleJanssen Enters Into Worldwide Exclusive License and Collaboration Agreement...
HORSHAM Pa. May 30 2017 PRNewswire Janssen Biotech Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has entered into a worldwide exclusive license and...
View ArticlePrebiotin Medical Director Interviewed by Peggy Lillis Foundation Executive...
HARRISBURG Pa. May 30 2017 PRNewswire Can Prebiotin play a role in managing and possibly preventing an illness that affects more than 500000 Americans every year with more than 29000 related deaths Yes...
View ArticleJanssen Protagonist Partner to Develop Oral IL23R Antagonist Peptide for IBD
Janssen Biotech and Protagonist Therapeutics inked a potentially $990 million global codevelopment and commercialization deal for Protagonist&39;s oral peptide IL23 receptor antagonist PTG200 for...
View ArticleJanssen Biotech Protagonist in Exclusive PTG200 Pact
To develop manufacture and commercialize PTG200 for Crohn's disease and ulcerative colitis
View ArticleProtagonist Janssen Ink Development Deal for Crohns Disease Drug
Protagonist Therapeutics work developing an inflammatory bowel disease drug that can be taken as a pill rather than injected now has fresh cash and the backing of a large pharmaceutical partner. Newark...
View ArticleProtagonist partners IBD compound PTG200 with Janssen Biotech
In a potential $990mm deal Protagonist Therapeutics Inc. is licensing Janssen Biotech Inc. exclusive global rights to develop manufacture and commercialize its PTG200 and related interleukin23 receptor...
View ArticleTaiwanJ Pharmaceuticals Co Ltd 6549 Pharmaceuticals Healthcare Deals and...
SummaryTaiwanJ Pharmaceuticals Co Ltd TaiwanJ is a pharmaceutical company that develops and commercialize firstinclass small molecules as TLR4 tolllike receptor 4 antagonists. TLR4 is a transmembrane...
View ArticleJanssen Enriches Crohn&39;s Portfolio In Deal For Protagonist&39;s Oral IL23...
J&J&39;s Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL23 inhibitor...&160;&160;&160;
View ArticleNeovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryNeovacs SA Neovacs is a biotechnology company which develops various therapeutic vaccines for autoimmune disorders inflammatory diseases and cancers. It offers TNF kinoid and IFNa kinoid...
View ArticleDiagnosis and management of inflammatory bowel disease in children
Inflammatory bowel diseases IBD including Crohns disease and ulcerative colitis are lifelong conditions that often begin in childhood. The implications of IBD are of particular importance in...
View Article